trending Market Intelligence /marketintelligence/en/news-insights/trending/bE5kG6j_g0UslHbdjDwFnA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Progyny prices Nasdaq IPO at $13 per share

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Progyny prices Nasdaq IPO at $13 per share

Progyny Inc. priced its IPO of 10 million common shares at $13 per share.

The company is offering 6.7 million common shares, while selling stockholders of the company are offering the remaining 3.3 million shares.

Certain selling stockholders also granted underwriters a 30-day option to buy up to an additional 1.5 million common shares at the same price.

Progyny's shares are expected to begin trading on the Nasdaq Global Select Market under the PGNY symbol on Oct. 25. The IPO is expected to close Oct. 29.

J.P. Morgan, Goldman Sachs & Co. LLC and BofA Securities are acting as joint lead book-running managers for the IPO, while Citigroup is acting as book-running manager. Piper Jaffray, SVB Leerink and TPG Capital BD LLC are acting as co-managers for the offering.

The New York-based company, which provides fertility services, previously said it plans to use the proceeds for general corporate purposes, working capital, operating expenses and capital expenditures.

Additionally, funds raised may be used for the acquisition of complementary businesses, services or technologies.